RETRACTION: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma (Retraction of Vol 34, Pg E104, 2016)

被引：0
|
作者：
Smyth
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 27期
关键词：
D O I：
10.1200/JCO.23.01358
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4448 / 4448
页数：1
相关论文
共 50 条
  • [1] RETRACTED: Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma (Retracted Article)
    Smyth, Mark J.
    Yagita, Hideo
    McArthur, Grant A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (12) : E104 - E106
  • [2] Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
    Lipson, Evan J.
    Drake, Charles G.
    CLINICAL CANCER RESEARCH, 2011, 17 (22) : 6958 - 6962
  • [3] Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center
    Afzal, Muhammad Z.
    Shirai, Keisuke
    MELANOMA RESEARCH, 2018, 28 (04) : 341 - 347
  • [4] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
    Reddy, Swathi B.
    Possick, Jennifer D.
    Kluger, Harriet M.
    Galan, Anjela
    Han, Dale
    JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
  • [5] Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
    Afzal, Muhammad Zubair
    Mercado, Rima R.
    Shirai, Keisuke
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [6] Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma
    Maker, AV
    Yang, JC
    Sherry, RM
    Topalian, SL
    Kannula, US
    Royal, RE
    Hughes, M
    Yellin, MJ
    Haworth, LR
    Levy, C
    Allen, T
    Mavroukakis, SA
    Attia, P
    Rosenberg, SA
    JOURNAL OF IMMUNOTHERAPY, 2006, 29 (04) : 455 - 463
  • [7] Anti-CTLA-4 antibodies A major therapeutic advance in metastatic melanoma treatment
    Robert, Caroline
    Mateus, Christine
    M S-MEDECINE SCIENCES, 2011, 27 (10): : 850 - 858
  • [8] Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
    Savoia, Paola
    Astrua, Chiara
    Fava, Paolo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2016, 12 (05) : 1092 - 1101
  • [9] Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases
    da Silva, Ines Pires
    Li, Isabel
    Ugurel, Selma
    Serra-Bellver, Patricio
    Andhale, Avanti
    Burnette, Hannah
    Aya, Francisco
    Conway, Jordan W.
    Braden, Jorja
    Carlino, Matteo S.
    Menzies, Alexander M.
    Weichenthal, Michael
    Mohr, Peter
    Gutzmer, Ralf
    Arance, Ana M.
    Johnson, Douglas B.
    Lorigan, Paul
    Schadendorf, Dirk
    Lo, Serigne N.
    Long, Georgina V.
    EUROPEAN JOURNAL OF CANCER, 2024, 205
  • [10] Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
    Simeone, Ester
    Ascierto, Paolo A.
    JOURNAL OF IMMUNOTOXICOLOGY, 2012, 9 (03) : 241 - 247
12345